Merck’s Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.
June 26 Merck’s Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.
The advisory committee on Thursday voted 5-2 to approve the monoclonal antibody-based vaccine for infants younger than 8 months old to protect them during their first seasonal exposure to RSV.
The recommended dosage is one shot of Enflonsia for infants who have not already obtained RSV protection via a vaccine their respective mothers might have received during their pregnancies.
